Important Safety Information
Methyldrostanolone was never approved for medical use and has no established human safety profile. It is a 17-alpha-alkylated steroid, a structural class associated with significant hepatotoxicity. Medical literature has documented numerous cases of cholestatic liver injury and acute kidney injury associated with methyldrostanolone use.
A comprehensive review identified methyldrostanolone as the most common anabolic steroid involved in drug-induced liver injury cases, with patients presenting with jaundice and pruritus, and 43% developing acute kidney injury.
Important
Non-Medical Use
Methyldrostanolone has no approved human indication. Non-medical use falls outside approved indications and carries significant health risks including severe hepatotoxicity, acute kidney injury, and endocrine suppression. Product strength and laboratory verification do not establish safety for human consumption.
Potential Adverse Effects
Hepatotoxicity: Methyldrostanolone is widely regarded as one of the most liver-toxic oral steroids available. Documented cases include cholestatic jaundice, elevated liver enzymes, and "bland" canalicular cholestasis on biopsy.
Kidney injury: Acute kidney injury has been reported in 43% of methyldrostanolone-related liver injury cases, with peak creatinine reaching 225 μmol/L.
Cardiovascular effects: Methyldrostanolone can decrease HDL cholesterol and increase LDL cholesterol, potentially accelerating atherosclerosis. Blood pressure elevation is also possible.
Androgenic effects: Acne, accelerated male-pattern hair loss, and increased body hair growth are possible. In women, virilization signs including voice deepening, hirsutism, and clitoromegaly may occur and can be irreversible.
Endocrine suppression: Methyldrostanolone suppresses endogenous testosterone production rapidly, leading to lethargy, reduced libido, testicular atrophy, and potential fertility impairment.
Conditions Requiring Medical Evaluation
Given the severity of potential adverse effects, any consideration of methyldrostanolone exposure warrants comprehensive medical evaluation including liver function tests, kidney function tests, lipid panel, blood pressure assessment, and hormonal evaluation. Individuals with pre-existing liver disease, kidney disease, cardiovascular disease, or psychiatric conditions are at heightened risk.
Monitoring During Therapy
There is no established monitoring protocol for non-medical methyldrostanolone use. For any human exposure, liver function tests, kidney function tests, lipid panel, blood pressure, and hormonal status should be assessed by a qualified healthcare professional. Bloodwork is strongly recommended before, during, and after any use.
Product Care
Storage & Handling
Store in a cool, dry place away from direct light and moisture. Keep the product in its original packaging and out of the reach of children. This product is not for human consumption.
Further Safety Information